PMC8299274_01
Clinical imaging, symptoms, and drug treatment data of patients with COVID-19. (A) CT image changes of patients with COVID-19 from first visit to discharge. (B) Changes in clinical symptoms in patients with COVID-19 during treatment after admission. (C) Medication information for patients with COVID-19 during hospitalization. Drug dosage: Recombinant human interferon alpha2b injection (6 million U, twice daily, aerosol inhalation); abidol hydrochloride granule (0.2 g, 3 times daily, oral administration); lopinavir/ritonavir (2 capsules, twice daily, oral administration); intravenous injection of human immunoglobulin (pH 4) (20 g, once daily, intravenous injection); methylprednisolone sodium succinate for injection (40 mg, once daily, subcutaneous injection); Lianhua Qingwen capsule (1.4 g, 3 times daily, oral administration); ribavirin injection (0.5 g, twice daily, intravenous injection); moxifloxacin hydrochloride tablets (400 mg, once daily, oral administration); moxifloxacin hydrochloride injection (0.4 g, once daily, intravenous injection); meropenem for injection (1 g, once per 8 h, intravenous injection); azithromycin for injection (0.5 g, once daily, intravenous injection); azithromycin tablets (0.5 g, once daily, oral administration); ceftriaxone sodium for injection (2 g, once daily, intravenous injection).
fpubh-09-687283-g0001.jpg
PMC8299274_01_fpubh-09-687283-g0001.jpg
F1
Viral pneumonia was also considered (Figure 1A). Physical examination on admission showed (Figure 1B) the following: body temperature, 37.6 C; blood pressure, 129/77 mmHg; respiratory rate, 18 times/min; pulse, 82 times/min; and blood oxygen saturation, 98%. In addition, patients were treated with antipyretic and fluid supplements according to their symptoms (Figure 1C). Re-examination chest CT showed that the lesion of the bilateral lung infection was larger and thicker than before, and the image showed significant progress compared to before (Figure 1A). The patient's third chest CT re-examination on February 11 showed no enlargement of the lesion, and the progress of the disease was basically under control (Figure 1A). The patient's fourth chest CT on February 14 showed scattered small nodules in the right lung and some absorption of the left lung lesions (Figure 1A). The detailed medication plans are shown in Table 1 and Figure 1C. On March 30, the re-examination CT showed that the lung images had returned to normal (Figure 1A).
Results of routine laboratory examination of patients with COVID-19 during admission. (A) Plasma D-dimer; (B) serum procalcitonin (PCT); (C) high-sensitivity C-reactive protein (Hs-CRP); (D) lipopolysaccharide (LPS); (E) white blood cell count; (F) classification count of lymphocyte subsets; (G) complement (C3, C4), immunoglobulin (IgA, IgG, IgM), and light chain (KAP, LAM: Immunoglobulin light chain kappa and lambda); (H) immunoglobulin E (IgE); (I) liver (ALB, albumin; ALT, alanine aminotransferase; GGT, gamma glutamyl transpeptidase) and kidney function (CREA, creatinine); (J) results of serum SARS-CoV-2 IgG/IgM detection in patients with COVID-19. The SARS-CoV-2 serum antibody (IgG/IgM) test kit (colloidal gold method) was provided by Zhuhai Lizhu Reagent Co., Ltd.; "-" represents negative, "+-" represents weak positive, and "+, 2+, 3+" represents positive, and it was enhanced step by step.
fpubh-09-687283-g0002.jpg
PMC8299274_01_fpubh-09-687283-g0002.jpg
F2
Disease progression was observed by continuous sample collection (Figures 2, 3).
Changes in nucleic acid detection in various patients with COVID-19. (A) Detection of SARS-CoV-2 nucleic acids in different samples of patients with COVID-19 during hospitalization. POS, Test result was positive; NEG, Test result was negative; N/a, No relevant tests were carried out. (B) Detection of SARS-CoV-2 nucleic acid in the feces of patients with COVID-19 pneumonia during hospitalization. Before February 25, 2020, the New Coronavirus 2019-nCOV nucleic acid detection kit (real-time fluorescent PCR method) provided by Shanghai Berger Biotechnology Co., Ltd. was used, and the New Coronavirus 2019-nCOV nucleic acid detection kit (real-time fluorescence PCR method) provided by Da'an gene Limited by Share Ltd. of Zhongshan University was used after February 25, 2020.
fpubh-09-687283-g0003.jpg
PMC8299274_01_fpubh-09-687283-g0003.jpg
F3
Disease progression was observed by continuous sample collection (Figures 2, 3).